In November 2017 Attana AB, Karolinska Universitetssjukhuset and KTH, Royal Institute of Technology was granted 4.8 MSEK from Vinnova. The grant is for development of bispecific antibodies targeting cancer cells and 600.000 SEK is dedicated for Attana. The project is now half way through and Attana has received a first payment of 300.000 SEK

The project aims at developing bispecific antibodies targeting cancer cells. One leg of the antibody is target towards the cancer cell and the other leg is to facilitate that the T-cells of the human immune system can dock to the cancer cells and lyse (kill) them. Attana’s part of the project is to characterize the antibodies interactions with the cancer cells and T-cells. Karolinska Universitetssjukhuset will provide the different antibodies and Attana and KTH will characterize the properties of the antibodies using different technologies. From those results the optimal antibody can be selected and further developed. The project also has a generic approach in aiming at improved development process for therapeutic antibodies prior to animal and clinical testing. The project is scheduled to be finalized at the end of 2019, when Attana will receive the remaining 300.000 SEK

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: [email protected] 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit or contact  [email protected]


Powered by WPeMatico